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Introduction 1 
 2 
The importance of developing safe and effective medicines for children has been 3 
recognised now. It has resulted in a paradigm shift in the profile of and the 4 
expectations for research with paediatric populations including policy changes in the 5 
global medicines environment. Regulations in both Europe and the USA mandate the 6 
development of paediatric medicines for new products that are still patent protected 7 
drugs and incentives are in place for the development of off-patent paediatric 8 
medicines  ((1, 2)). The formulation of paediatric medicines can be challenging since 9 
it is necessary to consider the diversity of this patient population in terms of age 10 
with associated compliance challenges such as acceptable palatability and potential 11 
safety concerns associated with excipients. Considering the issues in paediatric 12 
product development are shared among the stakeholders (governments, regulatory 13 
authorities, research institutions, pharmaceutical industry, and healthcare 14 
professionals), an integrated and co-coordinated approach is needed to address the 15 
issues and knowledge gaps. In 2007 European Paediatric Formulation Initiative 16 
(EuPFI) was launched with the objective of identifying the issues and challenges in 17 
paediatric drug formulation development. This article provides an overview of EuPFI 18 
consortium, highlighting the activities and efforts invested by EuPFI members. It also 19 
presents the challenges faced by the group members to advance and promote 20 
development of better medicines for the paediatric population.  21 
 22 
EuPFI Background 23 
 24 
Creation of the EuPFI consortium has been a major achievement in itself. EuPFI was 25 
created informally in 2007 based on the genuine willingness of formulation 26 
scientists’ aspiration to work together to in a non-competitive environment to 27 
understand better and learn how formulation research and development could 28 
better fulfill the needs of sick children. It evolved quickly into a structured 29 
established consortium with a mission to promote and facilitate the development of 30 
better and safe medicines for children through linking research, and information 31 
dissemination Seven founding members (GlaxoSmithKline, Novartis, Roche, 32 
University College London, AstraZeneca, Boeringer Ingelheim and MSD) raised 33 
sufficient funds to support the initial development of the EuPFI infrastructure. Since 34 
then much has been achieved, aims have evolved and are more refined, more 35 
specific and ambitious. Today, EuPFI is a consortium of 10 pharmaceutical 36 
companies, 5 universities, 1 hospital and uniquely, the European Medicines Agency 37 
(EMA) as an observer. Table 1 provides the goals and objectives of EuPFI consortium.  38 
 39 
Table 1: EuPFI objectives 40 
Identify the issues and challenges associated with development of paediatric 
formulation and consider ways towards better medications and clinically relevant 
dosage forms for children. 
Promote early pharmaceutical consideration for development of paediatric 
medicines. 
Identify potential information, knowledge, know-how gaps in the paediatric 
formulation development. 
Improve the availability of information of paediatric formulations. 
 41 
EuPFI Framework 42 
To enhance collaboration and build competencies, several membership options and 43 
criteria were defined (Associate, Sponsor and Observer) Figure 1. EMA acts as an 44 
observer to the group to observe proceedings/discussions in a passive way. They 45 
contribute to the exchange of comments and understanding of any 46 
recommendations raised by group members but does not influence the objectives of 47 
the EuPFI. The consortium members meet regularly (usually twice a year face to face 48 
and then over teleconferences as required). From time to time, other stakeholders 49 
are invited to attend the face to face meetings and present their work to the group. 50 
For example EuPATI (European Patients’ Academy on Therapeutic Innovation) 51 
expressed interest in being part of EuPFI and was invited to provide an overview to 52 
explore 53 
 54 
 55 
how to set up a two-way collaboration as EuPFI recognise the importance of Patient 56 
and Public involvement (PPI). EuPFI has five workstreams (Figure 1) each addressing 57 
a fundamental aspect of the development of medicines for children. Information on 58 
the work of each workstream including key deliverables for the near future are listed 59 
below.  60 
 61 
Age Appropriate Formulations Workstream (AAF) 62 
Children require age appropriate formulations that can deliver variable dose with 63 
age/weight, are safe and are adapted to their development and ability to take 64 
medicines. However there is limited knowledge about the age appropriateness of 65 
different dosage forms and limited availability of appropriate dosage forms even 66 
when the medicine is authorized for children (3). To overcome age appropriate 67 
formulation-related issues, healthcare professionals patients and parents have to 68 
resort to pharmaceutical compounding and drug manipulations. These are risky 69 
practice and can potentially cause harm, including toxicity or therapeutic failure, 70 
without knowing the pharmacokinetic and clinical outcome. The workstream 71 
activities are centered around the development and evaluation of medicines for 72 
marketing authorisations and guide the use of modifications to the dosage form in 73 
practice. The intent is to provide guidance to industry, regulators and academic 74 
researchers of the age-appropriateness of different pharmaceutical dosage 75 
forms.  An initial activity was therefore around the selection of age appropriate 76 
formulations, which requires a risk/benefit analysis on a case-by-case basis. The 77 
group proposed a structured integrated approach for assessing the risk and benefits 78 
of different pharmaceutical design options against pre-determined criteria relating 79 
to different routes of administration and formulation options including the safety of 80 
excipients, efficacy, usability, manufacturability, cost and patient access (4). 81 
Recognizing that there is confusion about the types of paediatric pharmaceutical 82 
preparation that are available for approval by medicines regulators, a reflection 83 
paper on ‘Preparation of medicines for children – a hierarchy of definition’ was 84 
published by AAF workstream members (5). The paper explores compounding and 85 
manipulation of medicines in relation to approval by medicines regulators to fulfil 86 
the needs of the individual patient. The team has proposed standardised definitions 87 
and terminology to clarify the types of paediatric pharmaceutical preparation. It 88 
aims to simplify strategies in product development to ensure quality and 89 
bioavailability. Another key aspect in development of age appropriate formulation is 90 
patient acceptability. Children and older adults differ in many aspects from the other 91 
age subsets of population and require particular considerations in medication 92 
acceptability. AAF workstream published a review highlighting the similarities and 93 
differences in two age groups in relation to factors affecting acceptability of 94 
medicines (6) and a paper highlighting how formulation factors affect the 95 
acceptability of different oral medicines in children (7). Currently the workstream is 96 
examining the acceptability of pharmaceutical products for children, evaluating 97 
formulation attributes, methodology development and criteria for acceptability 98 
assessments.  Moreover addressing manufacturing challenges in developing 99 
paediatric formulations and proposing novel solutions eg for poorly water-soluble 100 
drugs is underway in preparation through publications. Future tasks include 101 
considering industrial perspectives in harmonising formulation development for 102 
adults and children and collaborating with regulatory bodies on issues of age-103 
appropriateness of paediatric formulations. Another task would be to review the use 104 
of modified release formulations and different routes of administration in children to 105 
shift the emphasis to alternative routes which are understudied possibly and bridge 106 
the evidence gap. 107 
  108 
Biopharmaceutics  109 
 110 
Improving the understanding of biopharmaceutical assessment of paediatric 111 
pharmaceutical products enables more efficient development of medicines designed 112 
for children due to availability of appropriate in vitro tests that de-risk clinical 113 
assessment. The workstream has reviewed in vitro tests used in adult populations to 114 
determine what amendments are required to ensure they are relevant for a 115 
paediatric population (8). Specifically research undertaken by the biopharmaceutics 116 
workstream was to identify the relevant volume to classify a dose as highly soluble; 117 
values increased with age from a volume of 25 mL being  proposed for neonates 118 
compared to the adult volume of 250 mL. Dissolution conditions also suggested 119 
reduced volumes for younger children with <250mL for newborns and infants and 120 
larger volumes from 250-900mL for older children and adolescents. In addition, the 121 
applicability of the Biopharmaceutical Classification System (BCS) to paediatric 122 
populations was reviewed both using the literature (9) and from the results of a 123 
cross industry survey (10). The results of these reviews highlight several knowledge 124 
gaps in current methodologies in paediatric biopharmaceutics that are being 125 
addressed by the group. This includes better characterisation of the physiology and 126 
anatomy of the gastrointestinal tract (GI) tract in paediatric patients; 127 
characterisation of age-specific changes in drug permeation across the intestinal 128 
membrane and the development of biorelevant media and testing conditions for 129 
dissolution. 130 
 In collaboration with AAF, the current priority for the workstream is to understand 131 
the impact of co-administration of paediatric medicines with foods (such as apple 132 
sauce, pudding) that are commonly used to facilitate administration and improve 133 
compliance. There is no guidance on how the impact of manipulations is risk 134 
assessed from the laboratory to the patient. Non-standardised development 135 
approach for paediatric products increases the relative cost and timelines to support 136 
labelling claims. Biopharm group aims to address the risk level of co-administration 137 
of food with medicine on bioavailability based on a literature search and a discussion 138 
amongst experts. The group will also explore the biopharmaceutics tools used to 139 
predict food effects and evaluate how bridging may be achieved for in vitro 140 
prediction of in vivo performance in children. Future priority is to extend the 141 
understanding the biopharmaceutics of excipients, for exampler identifying how 142 
excipients can affect the absorption of drugs and GI physiology in children. 143 
 144 
Administration Devices 145 
It is undeniable that the need for and the type of paediatric administration device 146 
should be considered as an integral part of the paediatric product development 147 
process. The device should not only be technically capable of measuring the 148 
required/correct doses but also easily accessible and sufficiently user-friendly so as 149 
to facilitate compliance.  To address these issues, the devices workstream aims to 150 
identify and highlight current paediatric medicine administration devices practices 151 
and issues, with the ultimate aim of informing and facilitating the development and 152 
access to easy to use devices. 153 
The workstream has reviewed currently available paediatric administration devices 154 
(oral, pulmonary, parenteral, nasal and ocular routes) together with challenges 155 
associated with their use and recent developments (11, 12). In addition, as both the 156 
understanding and the usage of medical devices for oral and respiratory drug 157 
administration are heterogeneous among patients and caregivers, the workstream 158 
conducted a survey in hospital-based healthcare professionals (HCPs) (doctors, 159 
pharmacists and nurses) in six European countries to gain an understanding of HCP 160 
experiences of and opinions on oral and pulmonary paediatric administration 161 
devices (13). The countries selected (UK, Italy, Spain, France, Hungary and Germany) 162 
were considered to represent the geographical and cultural diversity of Europe. The 163 
results provided some valuable insights indicating that HCPs are aware of patients 164 
and caregivers having difficulty in using these types of devices.  The challenge was 165 
identifying and contacting the HCPs in each country due to the lack of direct access 166 
to HCPs as the group had no formal links to any hospitals or patient groups. To build 167 
upon these findings, the workstream is planning to conduct a similar survey in 168 
patients and their caregivers (parents, non-HCPs) to help identify areas for 169 
improvement. Long-term activities of the workstream include the development of 170 
guidance for conducting user handling studies, and an investigation into industry 171 
knowledge gaps for the development of administration devices and combination 172 
products, including regulatory requirements.  173 
 174 
Excipients 175 
 176 
One critical element in the development of paediatric formulations is the selection 177 
and use of excipients, as their safety in paediatric subpopulations is often unknown  178 
There are many issues (diseases specific, idiosyncratic reactions, physiological 179 
limitation) that have to be considered in the excipients selection process. Some 180 
excipients (e.g. propylene glycol, benzyl alcohol) are known to be less well tolerated 181 
by children depending upon the administration route, especially neonates and young 182 
children whose physiological system are still developing. Since excipients may be 183 
toxic, focused and detailed research is urgently needed to identify and support the 184 
use of excipients in different subsets of the paediatric population. Even though the 185 
demand for paediatric data on the safety of excipients has grown considerably, there 186 
is very limited paediatric excipient safety data in the public domain, and it is 187 
distributed throughout many sources. In an effort to address these availability and 188 
accessibility issues the excipients workstream has worked in collaboration with other 189 
networks such as United States Paediatric Formulation Initiative (USPFI) and Global 190 
Research in Paediatrics (GRiP) to develop the Safety and Toxicity of Excipients (STEP) 191 
database (14). This user-designed resource compiles the clinical, non-clinical, in-192 
vitro, review and regulatory information of excipients into one freely accessible 193 
source. The database  assists in screening and selecting of excipients for use in 194 
children and thus facilitates paediatric drug development (15). STEP launched in 195 
October 2014 has now information on 40 excipients with users from industry, 196 
academics, hospitals and regulators. It is accessible freely from EuPFI website and 197 
perceived as useful and an important addition to current resources (16). Existing 198 
data is updated regularly and additional excipients are added quarterly.  It is 199 
important to focus on the future by moving forward with the addition of excipients 200 
and enriching the existing content for the continuation of the use of the STEP 201 
database. Hence “Sponsor an Excipient” scheme has been introduced. The scheme 202 
allows end-users to include the excipients of their choice in the STEP database at 203 
minimal costs.  204 
 205 
Taste Assessment & Taste Masking (TATM) 206 
 207 
Improving the understanding of taste assessment tools and methodology used 208 
during the development of pharmaceutical products designed for paediatric 209 
populations is a must in parallel with better understanding of taste masking 210 
strategies that lead to the development of paediatric pharmaceutical products that 211 
have an acceptable taste.  The first inter-laboratory testing of electronic taste 212 
sensing systems was led by EuPFI (five participating centers including 3 EuPFI 213 
members), each working with the Insent (Insent Inc., Atsugi-Shi, Japan) e-tongue 214 
(17). Most of the published data reported good correlation between the human 215 
taste panel test and the electronic taste sensing systems. However, in most of these 216 
studies methods followed for bitterness prediction and constructing the correlation 217 
with human taste data were not always fully described. Electronic sensors give 218 
relative taste statement and should be validated with human taste panel tests. 219 
Ideally electronic tongues could be used for early screening of taste of pure APIs and 220 
optimisation of taste masked preclinical formulations in industry. 221 
However until it is demonstrated that electronic tongues can reliably predict 222 
bitterness intensity of the compounds, which were not used for developing 223 
calibration model, the use of this technology is still limited. A review paper to 224 
provide an overview of different approaches to taste masking APIs in paediatric oral 225 
dosage forms, with a focus on the tolerability of excipients used was also published 226 
(18) (19). Current TATM workstream focuses on 1) consolidating “Electronic tongue 227 
“user group, 2) the application of non-human in vivo, in silico and cell based taste 228 
assessment tools in pharmaceutical taste assessment. 229 
 230 
Reflection and challenges 231 
Nine years after its initiation, EuPFI is a well established collaboration of academia, 232 
industry, hospital and regulatory authorities, formed to harness the energies of 233 
these stakeholder groups for their common purpose and most importantly to 234 
provide the drive for finding solutions to issues in paediatric drug development. One 235 
of the strengths of the consortium has been its association with EMA, as observer on 236 
the group. The EMA representative participates in the consortium meetings and the 237 
group works together to update the research, identify gaps and discuss the 238 
regulatory needs and implications for paediatric product development. EuPFI 239 
members are invited to represent the group at several external meetings including 240 
EMA workshops. The annual conferences organised by EuPFI offers opportunity for 241 
paediatric formulation specialists to exchange and present recent accomplishments 242 
as well as discuss remaining challenges for the future with a vision of better 243 
medicines for children. So far the consortium has organized 7 annual conferences 244 
with up to 200 participants at a time. The 8th annual conference is scheduled for 21st 245 
and 22nd Sept 2016 in Lisbon, Portugal (http://www.eupfi.org/8th-conference/). The 246 
proceedings and selected invited publications are published in a special issue in 247 
International journal of pharmaceutics following to each conference (20-26). The 248 
collaborative effort has resulted in significant progress to date and the identification 249 
of new challenges to be met. However the process has not been a smooth journey. 250 
Many challenges came way through developing partnerships and collaboration.  251 
 252 
Shared vision and consortium management 253 
Given the diversity of approaches to the development of paediatric formulations 254 
consortium members worked to develop a shared vision. This is a long term and 255 
evolving process. As new members joined the consortium, the agenda of various 256 
stakeholders (patients, academia, clinicians, industry and policy makers) differ, and 257 
sometimes was difficult to reconcile. Maintaining a shared vision is a challenge. 258 
Another challenge is keeping it small and manageable. Due to complexity in 259 
managing larger organization, the consortium members preferred restricting it to 260 
smaller organization with 20- 25 core members. It was also agreed that, at least at 261 
first, EuPFI would be limited to Europe. However, later due to large interest from 262 
other countries such as India and US, it was decided to accept the members from 263 
other countries only if they were able to participate at face-to-face meeting held 264 
twice in a year. The success of the consortium has been to achieve a balance 265 
between the shared vision of the consortium, added value of each member and the 266 
specific aims of each workstream.  267 
 268 
Potential overlap between networks 269 
Considering large number of networks have established since the release of 270 
paediatric regulation and currently flourishing globally (Turner) such as GRiP, USPFI, 271 
some overlap between their activities is inevitable. Obviously, this might result in 272 
duplication of efforts and dissipation of resources.  Within EuPFI emphasis is made 273 
on establishing links and synergies .The aim is to  avoids any duplication of work and 274 
indeed encourage harmonization the efforts.  In 2014, EuPFI and Pediatric 275 
Formulation Working Group of the Innovative and Quality (IQ) Consortium (PFWGIQ) 276 
in collaboration conducted a systematic survey of researchers and regulators on 277 
current practices in paediatric product development (http://www.grip-278 
network.org/index.php/en/news/item/57). EuPFI members contributed to the 279 
paediatric formulation module of the GRiP e-Master of Science in Paediatric 280 
Medicines Development and Evaluation. ‘GRiP’ is an initiative funded by the 281 
European Union Seventh Framework Programme (FP7/2007-2013) to stimulate and 282 
facilitate the development and safe use of medicines in children through 283 
development of a comprehensive training programme and integrated use of existing 284 
research capacity. They were also actively involved in delivering ‘Meet the Expert in 285 
Paediatric Formulations’ webinars series (http://www.grip-286 
network.org/index.php/cms/en/Webinars - top). GRiP has partially funded the 287 
development, quality control and validation of the STEP database, which is 288 
developed in collaboration with USPFI. The USPFI was formed as a project of the 289 
Eunice Kennedy Shriver National Institute of Child Health and Human Development 290 
(NICHD) in 2005 to identify the issues and challenges in developing formulations for 291 
children. (27). As both EuPFI and USPFI group were working on similar issues it was 292 
decided to join the forces in the development of the STEP database.  The EuPFI 293 
excipients workstream worked with USPFI in collecting the information needs of the 294 
potential users and evaluating the need of the STEP database. USPFI also contributed 295 
to the development of methodologies for data collection, performing the usability 296 
study of the STEP database and continues to contribute via performing the searches 297 
on the additional excipients to be included in the database as part of expansion of 298 
the database. Additionally, there is overlap between EuPFI membership and the 299 
SPaeDD-UK project (Smart Paediatric Drug Development – UK, accelerating 300 
paediatric formulation development http://www.paediatricscienceuk.com),  funded by 301 
Innovate UK which aims to generate a structured approach to designing age-302 
appropriate medicines for children and technology for predicting their quality and 303 
performance (28).  304 
In addition, a first transatlantic workshop on paediatric formulation development is 305 
organised through M-CERSI (University of Maryland's Center of Excellence in 306 
Regulatory Science and Innovation funded by the FDA as a collaborative partnership 307 
between University of Maryland and FDA) and held in US in June 2016. It aims to 308 
provide an opportunity for experts to share their experiences and move towards 309 
consensus regarding best practices for developing age-appropriate drug products, 310 
which meet the needs of pediatric patients aligned with the requirements of 311 
regulatory agencies.  312 
 313 
Sustainability of the consortium 314 
There is the clear commitment of all partners to work together, to combine their 315 
expertise and strength, and to create a critical mass that is well integrated in the 316 
European pediatric formulation research area. However, unless stable funding can 317 
be secured, sustaining a consortium is truly challenging. The consortium has actively 318 
started to explore future options for sustaining the consortium. For example, the 319 
excipients workstream has recently launched the “sponsor an excipient” campaign. It 320 
will help finance excipients that have not yet been undertaken under the STEP 321 
database project and will help expedite the data curation process and maintain the 322 
database.  323 
 324 
Member’s commitment 325 
Maintaining a balance between the interests of members and their day-to-day 326 
responsibilities is another challenge. It depends heavily on the time and 327 
commitment of the members with conflicting priorities as they generally work on 328 
EuPFI activities in our own time. To date the support from the EuPFI members to 329 
formulating innovative ideas to issues in paediatric formulation development is what 330 
has kept the consortium active and on.  331 
 332 
Concluding remarks 333 
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